PIK3CA mutations were identified in 13.0% (474/3564) of samples in the pan‐cancer cohort, with the highest prevalence observed in uterine/endometrial (42.3%), breast (35.1%), cervical (27.7%) and ovarian (21.6%) cancers (Figure 1, Table S1). This evidence concerns the gene PIK3CA and cancer.